Natalizumab discontinuation in a Dutch real-world cohort
OBJECTIVE: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. METHODS: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. RESULTS: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. CONCLUSIONS: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advanc... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Reihe/Periodikum: | Coerver , E M E , Wessels , M H J , van Lierop , Z Y G , van Kempen , Z L E , Killestein , J & Strijbis , E M M 2021 , ' Natalizumab discontinuation in a Dutch real-world cohort ' , Multiple Sclerosis and Related Disorders , vol. 52 , 102974 , pp. 102974 . https://doi.org/10.1016/j.msard.2021.102974 , https://doi.org/10.1016/j.msard.2021.102974 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26687720 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://research.vumc.nl/en/publications/4d926165-34a6-4055-b395-4ddf894f7b0e |